NCT05511909View on ClinicalTrials.gov

Evaluating Buspirone to Treat Opioid Withdrawal

PHASE2RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

December 15, 2022

Primary Completion Date

January 31, 2027

Study Completion Date

March 31, 2027

Conditions
Opioid Use DisorderOpioid WithdrawalOpioid CravingAnxiety
Interventions
DRUG

Buspirone

Buspirone administration begins 2 days prior to opioid taper (study day -2) and continues until the second day of the post-taper observation phase (study day 7).

DRUG

Lofexidine

Lofexidine administration begins 2 days prior to opioid taper (study day -2) and continues until the second day of the post-taper observation phase (study day 7).

DRUG

Placebo

Participants administration begins 2 days prior to opioid taper (study day -2) and continues until the second day of the post-taper observation phase (study day 7).

Trial Locations (1)

21224

RECRUITING

Behavioral Pharmacology Research Unit, Baltimore

All Listed Sponsors
lead

Johns Hopkins University

OTHER